Coherus Biosciences, Inc. (CHRS)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
29.39+0.04 (+0.14%)
At close: 4:00 PM EDT
People also watch:
CACHPLCECBKSMRTBEBE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open29.36
Prev Close29.35
Bid27.72 x 100
Ask30.07 x 100
Day's Range28.83 - 29.97
52wk Range12.04 - 31.84
1y Target EstN/A
Market Cap1.27B
P/E Ratio (ttm)-4.46
BetaN/A
Volume214,042
Avg Vol (3m)406,419
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN)
    Insider Monkey12 days ago

    Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN)

    Coherus Biosciences Inc (NASDAQ:CHRS) submitted a biologics licensing application (BLA) for its lead biosimilar development candidate earlier this month, and is drawing a lot of speculative attention based on the potential impact of the drug it’s trying to get approved. Here is why. The drug in question is called CHS-1701 and it’s an oncology candidate. […]

  • Capital Cube13 days ago

    ETF’s with exposure to Coherus BioSciences, Inc. : August 15, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Coherus BioSciences, Inc. Here are 5 ETF’s with the largest exposure to CHRS-US. Comparing the performance and risk of Coherus BioSciences, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
    Capital Cube16 days ago

    Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Coherus BioSciences, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Coherus BioSciences, Inc. – Cardiome Pharma Corp., Acorda Therapeutics, Inc. and Agenus Inc. (CRME-US, ACOR-US and AGEN-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)